<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <p>Summary of Federal Policy Recommendations</p>
 </caption>
 <table frame="vsides" rules="groups">
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">1. Increase federal funding for SSPs and allow funds to be used to purchase sterile syringes in addition to other services.
     <break/> 2. Incentivize states to give more authority to local governments to establish SSPs and to eliminate barriers to sterile syringes, such as one-for-one needle exchange requirements.
     <break/> 3. Allow jurisdictions that have approved overdose prevention sites or supervised injection facilities to implement and evaluate the intervention in the United States.
     <break/> 4. Urge all states to expand Medicaid.
     <break/> 5. Fund demonstration projects and pilot studies to identify effective care models for comanagement of infectious diseases and SUD.
     <break/> 6. Increase funding for national and regional warmlines and peer-to-peer mentoring, programs for prescribers of MOUDs, and for cotreatment of related infections.
     <break/> 7. Eliminate the buprenorphine waiver, remove patient caps, and offer grant funding for case management and other support services to clinics and practices that prescribe MOUDs.
     <break/> 8. Increase funding and reimbursement for telehealth and other low-barrier access care delivery models.
     <break/> 9. Support implementation of universal HCV testing.
     <break/> 10. Develop a national surveillance system to report and track IDU-related infections to predict and respond to emerging epidemics.
     <break/> 11. Integrate MOUD and counseling services during incarceration.
     <break/> 12. Integrate screening for OUD and treatment with MOUD into jails and prisons.
     <break/> 13. Expand access to harm reduction during and after incarceration.
     <break/> 14. Allow states to initiate Medicaid coverage 30 days prior to release from criminal justice settings to facilitate care initiation and coordination during the transition to the community.
     <break/> 15. Fund research to evaluate non-HIV/ HCV related infections secondary to OUD/ SUD such as skin and soft tissue infections and risk of endocarditis with a specific focus on criminal justice involved populations.
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="fn-0100">
   <p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; MOUD, medication for treatment of opioid use disorder; OUD, opioid use disorder; SSPs, syringe services program; SUD, substance use disorder.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
